| Index | S&P 500 | P/E | 34.66 | EPS (ttm) | 8.06 | Insider Own | 1.33% | Shs Outstand | 164.60M | Perf Week | 4.67% |
| Market Cap | 45.98B | Forward P/E | 19.44 | EPS next Y | 14.37 | Insider Trans | -5.55% | Shs Float | 156.25M | Perf Month | 1.58% |
| Enterprise Value | 60.14B | PEG | 2.79 | EPS next Q | - | Inst Own | - | Short Float | 2.06% | Perf Quarter | 31.02% |
| Income | 1.38B | P/S | 2.71 | EPS this Y | 8.83% | Inst Trans | - | Short Ratio | 2.25 | Perf Half Y | 72.15% |
| Sales | 16.98B | P/B | 7.30 | EPS next Y | 11.00% | ROA | 4.60% | Short Interest | 3.22M | Perf YTD | 23.93% |
| Book/sh | 38.28 | P/C | 22.11 | EPS next 5Y | 12.41% | ROE | 21.95% | 52W High | 282.98 -1.28% | Perf Year | 28.23% |
| Cash/sh | 12.64 | P/FCF | 17.60 | EPS past 3/5Y | 11.08% 40.54% | ROIC | 8.32% | 52W Low | 154.50 80.82% | Perf 3Y | 47.85% |
| Dividend Est. | - | EV/EBITDA | 17.05 | Sales past 3/5Y | 4.21% 7.50% | Gross Margin | 26.23% | Volatility | 3.11% 2.88% | Perf 5Y | 12.26% |
| Dividend TTM | - | EV/Sales | 3.54 | EPS Y/Y TTM | 7.61% | Oper. Margin | 13.57% | ATR (14) | 7.77 | Perf 10Y | 269.04% |
| Dividend Ex-Date | - | Quick Ratio | 0.71 | Sales Y/Y TTM | 10.24% | Profit Margin | 8.10% | RSI (14) | 65.52 | Recom | 2.18 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.71 | EPS Q/Q | 12.10% | SMA20 | 4.99% | Beta | 1.15 | Target Price | 284.64 |
| Payout | 0.00% | Debt/Eq | 2.44 | Sales Q/Q | 8.74% | SMA50 | 6.13% | Rel Volume | 0.67 | Prev Close | 278.32 |
| Employees | 94,000 | LT Debt/Eq | 2.16 | Earnings | Oct 27 | SMA200 | 33.84% | Avg Volume | 1.47M | Price | 279.36 |
| IPO Date | May 09, 2013 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 3.89% 1.53% | Net Debt/EBITDA | 4.06 | Volume | 980,446 | Change | 0.37% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-14-26 | Reiterated | Stifel Nicolaus | Buy | $276 → $303 |
| Oct-07-26 | Reiterated | Mizuho | Outperform | $230 → $300 |
| Oct-07-26 | Reiterated | Barclays | Overweight | $210 → $300 |
| Sep-30-26 | Resumed | UBS | Buy | $240 → $345 |
| Sep-28-26 | Reiterated | Truist Securities | Buy | $245 → $329 |
| Sep-17-26 | Reiterated | Morgan Stanley | Equal Weight | $200 → $270 |
| Jul-29-26 | Reiterated | Robert W. Baird | $252 → $287 | |
| Jul-29-26 | Reiterated | RBC Capital | Outperform | $270 → $247 |
| Jul-29-26 | Reiterated | BMO Capital | Outperform | $250 → $270 |
| Jul-13-26 | Reiterated | Mizuho | Outperform | $215 → $230 |
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 16,983 | 16,310 | 15,405 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 12,528 | 10,880 | 10,030 | — | — | — | — | — | — | |
| Gross Profit | 4,455 | 5,430 | 5,375 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 2,058 | 1,988 | 1,992 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 92 | 1,260 | 1,181 | — | — | — | — | — | — | |
| Operating Income | 2,305 | 2,182 | 2,202 | — | — | — | — | — | — | |
| Interest Expense | 771 | 729 | 670 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 75 | 160 | 137 | — | — | — | — | — | — | |
| Net Income Before Taxes | 1,609 | 1,613 | 1,669 | — | — | — | — | — | — | |
| Income Taxes | 253 | 252 | 296 | — | — | — | — | — | — | |
| Consolidated Net Income | 1,375 | 1,360 | 1,373 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 1,356 | 1,361 | 1,373 | — | — | — | — | — | — | |
| Net Income | 1,375 | 1,360 | 1,373 | — | — | — | — | — | — | |
| EPS (Recurring) | 8.13 | 7.91 | 7.57 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 8.13 | 7.91 | 7.57 | — | — | — | — | — | — | |
| EPS (Diluted) | 8.06 | 7.84 | 7.49 | — | — | — | — | — | — | |
| EBITDA | 3,528 | 2,938 | 3,453 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 34.66 | 28.75 | 26.24 | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.75 | 2.38 | 2.31 | — | — | — | — | — | — | |
| Gross Margin | 26.23 | 33.29 | 34.89 | — | — | — | — | — | — | |
| Operating Margin | 13.57 | 13.38 | 14.29 | — | — | — | — | — | — | |
| Net Margin | 8.10 | 8.34 | 8.91 | — | — | — | — | — | — | |
| Shares Outstanding | 167 | 172 | 181 | — | — | — | — | — | — | |
| Market Capitalization | 46,653 | 38,771 | 35,568 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Berkshire James G. | See Remarks | Sep 02 '26 | Option Exercise | 131.82 | 5,381 | 709,323 | 13,558 | Sep 04 |
| Berkshire James G. | See Remarks | Sep 02 '26 | Sale | 261.33 | 2,668 | 697,228 | 10,890 | Sep 04 |
| STAUB W RICHARD | See Remarks | Aug 03 '26 | Sale | 232.68 | 5,500 | 1,279,740 | 13,312 | Aug 04 |
| Patel Bhavik | See Remarks | Jul 31 '26 | Sale | 235.27 | 1,855 | 436,426 | 1,348 | Aug 04 |
| BOUSBIB ARI | See Remarks | Jul 29 '26 | Sale | 245.51 | 106,279 | 26,092,072 | 885,868 | Jul 31 |
| Sherbet Eric | See Remarks | Jul 29 '26 | Sale | 249.16 | 5,000 | 1,245,800 | 20,999 | Jul 31 |
| Cherofsky Keriann | See Remarks | Jul 29 '26 | Sale | 245.21 | 558 | 136,827 | 2,989 | Jul 31 |
| BOUSBIB ARI | See Remarks | Jul 29 '26 | Option Exercise | 78.21 | 156,206 | 12,216,871 | 992,147 | Jul 31 |
| BOUSBIB ARI | See Remarks | Dec 18 '25 | Option Exercise | 59.90 | 50,000 | 2,995,000 | 857,163 | Dec 19 |
| BOUSBIB ARI | See Remarks | Dec 18 '25 | Sale | 222.43 | 36,564 | 8,132,931 | 820,599 | Dec 19 |
| Sherbet Eric | See Remarks | Oct 29 '25 | Option Exercise | 131.82 | 10,000 | 1,318,200 | 31,108 | Oct 31 |
| Sherbet Eric | See Remarks | Oct 29 '25 | Sale | 219.70 | 4,000 | 878,800 | 27,108 | Oct 31 |
| BOUSBIB ARI | See Remarks | Oct 29 '25 | Option Exercise | 59.90 | 77,592 | 4,647,761 | 884,755 | Oct 31 |
| BOUSBIB ARI | See Remarks | Oct 29 '25 | Sale | 220.33 | 56,557 | 12,461,120 | 828,198 | Oct 31 |
| Cherofsky Keriann | See Remarks | Jul 23 '25 | Sale | 191.53 | 549 | 105,150 | 2,910 | Jul 25 |